Mean platelet volume in children with familial Mediterranean fever

Balahan Makay1, Zeynep Türkyilmaz, Erbil Unsal

  • 1Department of Pediatrics, Division of Pediatric Immunology and Rheumatology, Dokuz Eylül University Hospital, Balçova 35340, Izmir, Turkey. balahan.bora@deu.edu.tr

Clinical Rheumatology
|March 14, 2009
PubMed

Insights

Familial Mediterranean Fever (FMF) patients had lower mean platelet volume (MPV) during attacks. However, MPV levels in attack-free FMF patients did not differ from healthy individuals, suggesting no increased atherosclerosis risk.

Area of Science:

  • Hematology
  • Rheumatology
  • Pediatrics

Background:

  • Familial Mediterranean Fever (FMF) is an inherited autoinflammatory disorder causing recurrent serositis.
  • Emerging evidence links FMF to an elevated risk of atherosclerosis.
  • Mean Platelet Volume (MPV) indicates platelet activation and is associated with atherosclerosis risk.

Purpose of the Study:

  • To investigate Mean Platelet Volume (MPV) levels in pediatric patients with Familial Mediterranean Fever (FMF) during active disease flares and remission.
  • To assess MPV as a potential marker for atherosclerosis risk in pediatric FMF.

Main Methods:

  • Retrospective analysis of MPV, platelet count (PLT), and inflammatory markers (ESR, CRP, WBC) in 48 pediatric FMF patients during attacks.
  • Comparison of MPV levels in 63 FMF patients during attack-free periods and 49 healthy controls.
  • Statistical analysis to determine differences and correlations between MPV, PLT, and disease status.

Main Results:

  • MPV was significantly lower in pediatric FMF patients during attacks compared to their attack-free periods (p=0.00).
  • No significant difference in MPV was observed between FMF patients in attack-free periods and healthy controls (p=0.38).
  • Mean platelet counts were higher in FMF patients during attacks than in controls (p=0.02), with an inverse correlation between MPV and PLT in the attack-free period (r=-0.446, p=0.01).

Conclusions:

  • Pediatric FMF patients on colchicine treatment do not exhibit elevated MPV levels, a marker of platelet activation and potential atherosclerosis risk, during attack-free periods.
  • The findings suggest that FMF, particularly in pediatric patients on treatment, may not be associated with an increased risk of atherosclerosis as indicated by MPV.
  • Further research is needed to fully elucidate the relationship between FMF, inflammation, platelet activation, and long-term cardiovascular outcomes.